This company has been acquired
Vapotherm (VAPO) Stock Overview
A medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
VAPO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Vapotherm, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.17 |
| 52 Week High | US$3.44 |
| 52 Week Low | US$0.70 |
| Beta | -1.1 |
| 1 Month Change | 0.59% |
| 3 Month Change | 2.60% |
| 1 Year Change | -22.22% |
| 3 Year Change | -98.97% |
| 5 Year Change | -97.04% |
| Change since IPO | -98.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| VAPO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.5% | 5.7% | -0.7% |
| 1Y | -22.2% | -17.8% | 20.3% |
Return vs Industry: VAPO underperformed the US Medical Equipment industry which returned 18.6% over the past year.
Return vs Market: VAPO underperformed the US Market which returned 27.6% over the past year.
Price Volatility
| VAPO volatility | |
|---|---|
| VAPO Average Weekly Movement | 1.7% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VAPO's share price has been volatile over the past 3 months.
Volatility Over Time: VAPO's weekly volatility has decreased from 27% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 182 | Joe Army | www.vapotherm.com |
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation.
Vapotherm, Inc. Fundamentals Summary
| VAPO fundamental statistics | |
|---|---|
| Market cap | US$13.61m |
| Earnings (TTM) | -US$54.42m |
| Revenue (TTM) | US$70.92m |
Is VAPO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VAPO income statement (TTM) | |
|---|---|
| Revenue | US$70.92m |
| Cost of Revenue | US$37.71m |
| Gross Profit | US$33.21m |
| Other Expenses | US$87.63m |
| Earnings | -US$54.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.71 |
| Gross Margin | 46.82% |
| Net Profit Margin | -76.74% |
| Debt/Equity Ratio | -145.6% |
How did VAPO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/19 14:35 |
| End of Day Share Price | 2024/09/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vapotherm, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Hopkins | BofA Global Research |
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |